Condition: Acute Lymphocytic Leukemia · Sponsor: Leland Metheny
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
This description comes directly from the study's public registry record.
Leland Metheny, MD · 1-800-641-2422 · CTUReferral@UHhospitals.org
Ron Sobecks, MD · 216-444-6833 · sobeckr@ccf.org
Always discuss trial participation with your own doctor first.
| The University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Active Not Recruiting |
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland, Ohio, United States | Recruiting |
| Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center | Cleveland, Ohio, United States | Active Not Recruiting |
| The James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03104491